

A. FULL NAME:	Dey	Dr. Sayak		B. DOB:	24/09/1991
	Last Name	First Name	Middle Name		(dd/mm/yyyy)
C. DESIGNATION					
D. ROLE IN THE STUDY		☐ Investigator ☒ Sub-Investigator ☐ Study Coordinator ☐ Study Nurse ☐ Videographer ☐ Others (please specify) :			
E. CONTACT DETAILS					
Site Address:					
Tata Medical Center 14 Major Arterial Road(E-W), Newtown, Rajarhat, Kolkata-700160, West Bengal, India		Landline:			
		Mobile: +91-9749955500			
		Fax:			
		Email: sayakdey240991@gmail.com			
Residential Address:		Website: (Hospital website) www.tmckolkata.com			
F. ACADEMIC QUALIFICATIONS (Current Qualification First)					
<u>Degree/ Certification</u>		<u>Date</u> (dd/mm/yyyy)	<u>Institution, Country</u>		
DM		2023	Tata Memorial Hospital, Mumbai, India		
MD		2019	Tata Memorial Hospital, Mumbai, India		
MBBS		2015	West Bengal University of Health Sciences, Kolkata, India		
G. TRAINING DETAILS					
Training Type [Webex, Online Certification, Investigators Meet, Site Initiation, Other F2F, etc.]	Topics Covered [ICH GCP, Indian Regulations, Study specific, etc.]		Date of Completion of Training	Certificate/ Training Log enclosed [Yes/ No]	
Online	ICH GCP Guidelines		06/02/2025	Yes	
	Indian GCP Guidelines				
	New Drugs and Clinical Trials Rules 2019 and amendments				
	ICMR Guidelines				
	Site SOPs Version X dated DD MMM YY				
	Investigators Meet for Study ABC				
	< Study specific				


H. CURRENT AND PREVIOUS POSITIONS INCLUDING ACADEMIC APPOINTMENTS (Current Position First)		
Dates In Years	Title	Institution/Company, Country
Jan 2025-Continue	Consultant	Department of Medical Oncology, Tata Medical Center, Kolkata, India
Jan 2024 – Dec 2024	Ad-Hoc Assisat Professor	Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
Dec 2020 - Dec 2023	Senior Registrar (DM Resident)	Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India
Aug 2019 – July 2020	Senior Registrar	Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India
May 2016 – June 2019	Junior Resident	Department of Radiation Oncology, Tata Memorial Hospital, Mumbai, India

I. BRIEF SUMMARY OF RELEVANT CLINICAL RESEARCH EXPERIENCE:			
Therapeutic Area	Phase of Trial (I, II, III, IV)	Period	No. of trials in therapeutic area
Prostate Cancer	III	Ongoing	1
Breast Cancer	III	Ongoing	3
Lung Cancer	III	Ongoing	2
Ovarian Cancer	III	Ongoing	1

J. SEMINARS AND CONFERENCES ATTENDED
NA

K. PUBLICATIONS AND PAPERS (If Any)
- Sneha Tandon , Nehal Khanna , Rahul Chivate , Sayak Dey et al, Solitary Bone Plasmacytoma of Humerus Presenting as a Nonhealing Fracture in a Child: A Rare Entity. <i>J Pediatr Hematol Oncol</i>. 2022 Jan 1;44(1):e233-e236 - Vedang Murthy , Shirley Lewis , Sadhana Kannan, Chira Ranjan Khadanga , Venkatesh Rangarajan , Kishore Joshi , Minakshi Gandhi , Sayak Dey et al, Submandibular function recovery after IMRT in head and neck cancer: A prospective dose modelling study. <i>Radiother Oncol</i> . 2018 Oct;129(1):38-43. doi: 10.1016/j.radonc.2018.02.021. Epub 2018 Apr 30. - Goutam Santosh Panda, Vanita Noronha, Vijay Patil, Amit Joshi, Nandini Menon, Rajiv Kumar, Trupti Pai, Omshree Shetty, Amit Janu, Nivedita Chakrabarty, Nilendu Purandare, Sayak Dey and Kumar Prabhash et al, Clinical outcomes of ROS1-positive non-small cell lung cancer with limited access to ROS1-tyrosine kinase inhibitors (TKIs): experience from an Indian tertiary referral centre. <i>ecancer</i> 2024, 18:1654 https://doi.org/10.3332/ecancer.2024.1654 - Lenalidomide following whole-brain radiotherapy in patients with primary central nervous system lymphoma ineligible for intensive systemic therapy. Bhausaheb Bagal, Rup Sarma, Sayak Dey et al. <i>Br J Haematol</i> . 2023 Apr;201(1):150-153. doi: 10.1111/bjh.18659. Epub 2023 Jan 22 - Vijay Maruti Patil et al, Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation. <i>J Clin Oncol</i> . 2023 May 1;41(13):2350-2361. doi: 10.1200/JCO.22.00980. Epub 2023 Jan 27. - Prognostic reclassification and survival outcomes in intermediate- and poor-risk nonseminomatous germ cell tumors (NSGCT). Kunal Naishadh Jobanputra, Gagan Prakash, Amandeep Arora, Bhagyashri Jadhav, Mahendra Pal, Akash Pawar, Sayak Dey et al. https://ascopubs.org/doi/pdf/10.1200/JCO.2024.42.16_suppl.5033

L. MEMBERSHIP[S] (If Any)			
• Indian Society of Medical and Pediatric Oncology (ISMPO) • European Society Of Medical Oncology(ESMO) • Association of Radiation Oncologists of India(AROI)			
M. MEDICAL REGISTRATION NUMBER:	72499	REGISTERED IN STATE/COUNTRY:	West Bengal Pharmacy Council
MEDICAL LICENSE: Signed & dated enclosed	Yes	Date of Expiry of License, if any	NA
By signing this CV, I confirm that the information provided on this CV is accurate and reflects my current employment and qualifications:			
N. SIGNATURE: <u>Sayak Dey</u>		Date of Signature 6/2/25	



WEST BENGAL MEDICAL COUNCIL

IB 196, Sector-III, Salt Lake
Kolkata - 700 106

Additional Qualification / Change of Surname Change of Address Registration Certificate

Registration No. : 72499
Date of Original Registration : 07-04-2015
Name : DEY
DR. SAYAK
Father's Name : SWAPAN KUMAR DEY
Sex : Male
Address : Permanent : L / 64 / 1104 SPRIHA APPT.
SP SHUKHOBISHTI, NEWTOWN AA III,
PATHARGHATA, KOLKATA - 700135.
Present : L / 64 / 1104 SPRIHA APPT.
SP SHUKHOBISHTI, NEWTOWN AA III,
PATHARGHATA, KOLKATA - 700135.



Qualification : Basic : M B B S (West Bengal University of Health Sciences), 2015
Additional : M D (Radiation Oncology) (Homi Bhabha National Institute), 2019
● [Regd on 08-10-2020]


Signature of Applicant Full : *Soyak Dey*

Specimen : *Soyak Dey*

Date : 08-10-2020

[Signature]
Registrar, WBMC

Soyak Dey
8/2/25



Enabling research by sharing knowledge

Hereby Certifies that

SAYAK DEY

has completed the e-learning course

**ICH GOOD CLINICAL
PRACTICE E6 (R2)**

with a score of


94%

on

06/02/2025

This e-learning course has been formally recognised for its quality and content by the following organisations and institutions

*This ICH E6 GCP Investigator Site Training meets the Minimum Criteria for ICH GCP Investigator Site Personnel Training identified by **TransCelerate BioPharma** as necessary to enable mutual recognition of GCP training among trial sponsors.*



Global Health Training Centre
globalhealthtrainingcentre.org/elearning

Certificate Number 6f410c30-2310-48c2-a7d7-3f6d4e13c925 Version number 0

Sayak Dey
6/2/25